Dr. Frederick (Fritz) Roth is an inaugural Canada Excellence
Research Chair in Integrative Biology and a Senior Investigator at the
Lunenfeld-Tanenbaum Research Institute. Known worldwide for his work in
computational biology and genomics, Dr. Roth is jointly appointed at
the University of Toronto's Terrence Donnelly Centre for Cellular
and Biomolecular Research.
Dr. Roth completed his PhD in biophysics at Harvard University in
1998, after studying both physics and molecular and cell biology at the
University of California, Berkeley. His most recent position before
joining the Lunenfeld was at Harvard Medical School, where he was an
Associate Professor in the Department of Biological Chemistry and
His research focuses on developing technologies to more efficiently
relate genes to the functioning of living systems and human diseases.
These new technologies will accelerate researchers' studies of
genes, their functions and how these functions interact to form living
Building on their previous work in experimental and computational
genomics, Dr. Roth's team will collaborate with other Lunenfeld
researchers in the Systems Biology group to develop new technologies
for revealing gene functions, the pathways they encode and how these
genes and pathways are related to human diseases. Dr. Roth's group
is harnessing â€œnext generationâ€ DNA sequencing technologies to
systematically measure the effects of multiple genetic changes, and to
map protein interactions.
Large-scale experimentation on biological model systems by Dr. Roth
and others in the Systems Biology group is uncovering fundamental
aspects of protein, cell and organismal function to better understand
human health and disease.
Early work by Dr. Roth demonstrated that DNA sequence elements
controlling genes can be automatically discovered using large-scale
measurements of the levels at which genes are activated.
His group has extensively studied the networks of interactions
between proteins in yeast, worms, plants and humans. More
recently, Dr. Roth's team has computationally prioritized
candidate disease genes so that researchers can focus efforts on the
genes most likely to impact human health.